Developer of monoclonal antibody medicines (mAbs) intended to discover, develop, and commercialize medicines based on mAbs therapeutics. The company's medicines leverage novel technologies to develop therapeutics, enabling researchers to research on the latest medical technology based drugs for oncology and autoimmune disease.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Early Stage VC | 24-Sep-2020 | $9.8M | 000.00 | 0000 | Completed | Generating Revenue |
3. Early Stage VC | 16-Aug-2019 | 00.00 | 000.00 | 000.00 | Completed | Generating Revenue |
2. Early Stage VC (Series A) | 03-Apr-2016 | $15.7M | $18.1M | Completed | Generating Revenue | |
1. Seed Round | 22-Dec-2014 | $2.35M | $2.35M | Completed | Generating Revenue |
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
B Shares | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
Preference | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
A Shares | 2,171,715 | $0.001306 | $2.59 | $2.59 | 1x | $2.59 | 1.73% | |
Seed | 1,500,000 | $0.001306 | $1.31 | $1.31 | 1x | $1.31 | 17.12% |
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialCompany Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Apogenix | Venture Capital-Backed | Heidelberg, Germany | 00 | 000.00 | 0000000000 | 000.00 |
000 00000000000000 | Corporation | Nantes, France | 00 | 000.00 | 000000000 | 000.00 |
0000000 | Corporation | Princeton, NJ | 00 | 00000 | 000000000 | 00000 |
000000 00000000 | Formerly VC-backed | Foster City, CA | 00000 | 00.000 | 000000&0 | |
0000000 0000000000 | Formerly VC-backed | Heidelberg, Germany | 000 | 00000 | 00000000000 | 00000 |
Name | Representing | Role | Since |
---|---|---|---|
Steve Holmes Ph.D | Capella BioScience | Founder, Board Member & Chief Operating Officer | 000 0000 |
William Harrington MD | Osage Venture Partners | Board Observer | 000 0000 |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Medicxi | Venture Capital | Minority | 000 0000 | 000000 0 | |
Osage University Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
Advent Life Sciences | Venture Capital | Minority | 000 0000 | 000000 0 | |
Data Collective | Venture Capital | Minority | 000 0000 | 000000 0 | |
Farzad Nazem | Angel (individual) | Minority | 000 0000 | 000000 0 |